Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.440.02%
QQQ
715.040.02%
BTC/USD
76999.860.2604%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Pelthos Therapeutics Inc

PTHSAMEX
Trade with Public
Trade with Public
$21.90
-0.53-2.36%
At close: Sep 11, 5:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Pelthos Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pelthos Therapeutics (PTHS).

Price Target Range — 5 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingBuy# Analysts6Avg. Consensus PT$55

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026OppenheimerJeff JonesPT CutOutperform$66→$64
May 15, 2026OppenheimerJeff JonesPT RaiseOutperform$62→$66
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $66 to $64.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $62 to $66.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $60 to $62.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Pelthos Therapeutics (AMEX:PTHS) with a Buy and maintains $60 price target.
Benzinga Newsdesk

This Jazz Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Top analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, initiations. See what they think of JAZZ stock.
Avi Kapoor

PRO
Piper Sandler Initiates Coverage On Pelthos Therapeutics with Overweight Rating, Announces Price Target of $48

Piper Sandler analyst David Amsellem initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Overweight rating and announces Price Target of $48.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved